The “2025 Pharmaceutical Innovation Policy Forum”, hosted by the China Pharmaceutical Innovation and Research Development Association (PhIRDA), co-organized by the Medicinal Policy Specialty Committee and the Innovation R&D Services Specialty Committee of PhIRDA, and supported by the Science and Technology Commission of Minhang District, Shanghai Municipality, was held in Shanghai on May 24. The forum brought together well-known experts and scholars to discuss new policies, integrate the allocation of innovation resources across the entire chain, and promote China’s innovation to enter a high-quality development track. Dr. Hu Yuanjia, professor at the Institute of Chinese Medical Sciences and director of the Centre for Pharmaceutical Regulatory Sciences (CPRS) at the University of Macau, was invited to attend the forum and served as a guest for the theme discussion session.

The forum focused on two major themes: “From trade frictions to industrial upgrading: the way out for Chinese pharmaceutical companies” and “Commercial insurance helps pharmaceutical innovation and boosts industry confidence.” In the theme discussion session titled “Coexistence of crises: the way out for China’s pharmaceutical innovation under the new situation,” director Hu Yuanjia introduced the current scientific research at the University of Macau. He noted that since 2015, China’s pharmaceutical industry has undergone significant changes. He believed that as China’s innovative achievements gain international recognition, the pharmaceutical industry will achieve more success.

Prof. Hu Yuanjia, director of CPRS